PE02512008A1 - Uses DPP IV inhibitors - Google Patents

Uses DPP IV inhibitors

Info

Publication number
PE02512008A1
PE02512008A1 PE2007000540A PE0005402007A PE02512008A1 PE 02512008 A1 PE02512008 A1 PE 02512008A1 PE 2007000540 A PE2007000540 A PE 2007000540A PE 0005402007 A PE0005402007 A PE 0005402007A PE 02512008 A1 PE02512008 A1 PE 02512008A1
Authority
PE
Peru
Prior art keywords
yl
methyl
amino
dpp iv
uses
Prior art date
Application number
PE2007000540A
Other languages
Spanish (es)
Inventor
Klaus Dugi
Michael Mark
Frank Himmelsbach
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP06009203 priority Critical
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE02512008A1 publication Critical patent/PE02512008A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38235138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE02512008(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/866Diabetes

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I o II DONDE R1 ES [1,5]NAFTIRIDIN-2-IL)METILO, (QUINAZOLIN-2-IL)METILO], ENTRE OTROS; REFERS TO A compound of formula I or II wherein R1 is [1,5] naphthyridin-2-yl) methyl, (QUINAZOLIN-2-YL) METHYL], among others; R2 ES 3-(R)-AMINO-PIPERIDIN-1-ILO,(2-AMINO-2-METIL-PROPIL)-METILAMINO o (2-(S)-AMINO-PROPIL)-METILAMINO. R2 is 3- (R) -amino-piperidin-1-yl, (2-AMINO-2-methylpropyl) methylamino or (2- (S) -amino-propyl) -methylamino. SON COMPUESTOS PREFERIDOS : 1-[(4-METIL-QUINAZOLIN-2-IL)METIL]-3-METIL-7-(2-BUTIN-1-IL)-8-(3-(R)-AMINO-PIPERIDIN-1-IL)-XANTINA; Preferred compounds: 1 - [(4-METHYL-QUINAZOLIN-2-YL) METHYL] -3-METHYL-7- (2-butyn-1-yl) -8- (3- (R) -amino-piperidin- 1-yl) xanthine; 1-[([1,5]-NAFTIRIDIN-2-IL)METIL]-3-METIL-7-(2-BUTIN-1-IL)-8-((R)-3-AMINO-PIPERIDIN-1-IL)-XANTINA; 1 - [([1,5] -naphthyridin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8 - ((R) -3-AMINO-PIPERIDINE-1- IL) xanthine; ENTRE OTROS. AMONG OTHERS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ALSO it REFERS TO A pharmaceutical composition and method of preparation. LOS COMPUESTOS DESCRITOS SON INHIBIDORES DE DPP IV, UTILES EN EL TRATAMIENTO DE PIE DIABETICO, ULCERA ASOCIADA A DIABETES, HIPERLIPIDEMIA, DISLIPIDEMIA DIABETICA, INSUFICIENCIA CARDIACA The disclosed compounds are inhibitors of DPP IV, useful in the treatment of diabetic foot ulcer associated with diabetes, hyperlipidemia, dyslipidemia DIABETIC, congestive heart
PE2007000540A 2006-05-04 2007-05-02 Uses DPP IV inhibitors PE02512008A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06009203 2006-05-04

Publications (1)

Publication Number Publication Date
PE02512008A1 true PE02512008A1 (en) 2008-04-25

Family

ID=38235138

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011000120A PE02352011A1 (en) 2006-05-04 2007-05-02 pharmaceutical combinations comprising metformin and linagliptin
PE2007000540A PE02512008A1 (en) 2006-05-04 2007-05-02 Uses DPP IV inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011000120A PE02352011A1 (en) 2006-05-04 2007-05-02 pharmaceutical combinations comprising metformin and linagliptin

Country Status (33)

Country Link
US (6) US8232281B2 (en)
EP (4) EP2397142A3 (en)
JP (9) JP5734564B2 (en)
KR (7) KR101558938B1 (en)
CN (6) CN108635355A (en)
AR (1) AR060757A1 (en)
AU (1) AU2007247141B2 (en)
BR (1) BRPI0711308A2 (en)
CA (4) CA2833705C (en)
CL (3) CL2012002528A1 (en)
CY (1) CY1115350T1 (en)
DK (1) DK2015754T3 (en)
EA (2) EA200802204A1 (en)
EC (1) ECSP088866A (en)
ES (1) ES2474866T3 (en)
HK (1) HK1204548A1 (en)
HR (1) HRP20140645T1 (en)
IL (1) IL195031D0 (en)
ME (1) ME01787B (en)
MX (2) MX2008014025A (en)
NO (1) NO20084341L (en)
NZ (2) NZ572863A (en)
PE (2) PE02352011A1 (en)
PH (2) PH12013501791A1 (en)
PT (1) PT2015754E (en)
RS (1) RS53272B (en)
SG (1) SG171648A1 (en)
SI (1) SI2015754T1 (en)
TW (2) TWI500423B (en)
UA (1) UA102669C2 (en)
UY (1) UY30321A1 (en)
WO (1) WO2007128761A2 (en)
ZA (1) ZA200808282B (en)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1757606T1 (en) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Xanthinderivatives for use as medical agents and the preparation thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (en) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their preparation and their use as medicaments
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (en) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8- (piperazin-1-yl) -and 8 - ([1,4] diazepan-1-yl) -xanthines, their preparation and their use as medicaments
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (en) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-amino-piperidin-1-yl] -xanthines, their preparation and use as medicaments
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (en) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg New imidazoles and triazoles, their preparation and use as medicaments
DE102004043944A1 (en) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as medicaments
DE102004044221A1 (en) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl-xanthine, their production and their use as medicaments
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg A process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
US7713938B2 (en) * 2005-05-03 2010-05-11 Boehringer Ingelheim International Gmbh Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as medicaments
CA2621314A1 (en) * 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
UY30082A1 (en) 2006-01-11 2007-08-31 Boehringer Ingelheim Int crystalline form of 1- (1-methylethyl) -4` - ((2-fluoro-4-methoxyphenyl) methyl) -5`- methyl-1H-pyrazol-3`-OBD-glucopyranoside, a method for their preparation and use thereof for preparing medicaments
PE06972008A1 (en) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Benzonitrile derivatives Glucopyranosyl-substituted, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE02352011A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int pharmaceutical combinations comprising metformin and linagliptin
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US20080020987A1 (en) * 2006-07-20 2008-01-24 Waldemar Pfrengle Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CA2667550A1 (en) * 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
PE06032009A1 (en) * 2007-08-16 2009-06-11 Boehringer Ingelheim Int pharmaceutical composition comprising an SGLT2 inhibitor and a DPP IV
PE09382009A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int pharmaceutical composition comprising a benzene derivative substituted glucopyranosyl
UY31291A1 (en) * 2007-08-16 2009-03-31 A pharmaceutical composition comprising a pyrazole derivative-0-glucoside
UY31290A1 (en) * 2007-08-16 2009-03-31 A pharmaceutical composition comprising a pyrazole derivative-o-glucoside
EP2217602B1 (en) * 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
AU2009205060C1 (en) * 2008-01-17 2013-12-19 Mitsubishi Tanabe Pharma Corporation Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
KR20120003868A (en) * 2009-03-31 2012-01-11 베링거 인겔하임 인터내셔날 게엠베하 1-heterocyclyl-1,5-dyhydro-pyrazolo[3,4-d]pyrimidine-4-one derivatives and their use as pde9a modulators
US8623879B2 (en) * 2008-04-02 2014-01-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int pharmaceutical composition comprising an inhibitor of dipeptidyl peptidase-4 (DPP4) and a companion drug
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "Treatment for diabetes in patients unsuitable for therapy with metformin"
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
JP5453431B2 (en) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Their use for the treatment of pyrazolopyrimidine and cns disorders
RU2011113823A (en) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Combination therapy for the treatment of diabetes and related conditions it
JP2012509892A (en) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ,インク. The method of the composition and use containing Satiogen acids
WO2010072776A1 (en) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (en) 2009-01-29 2011-03-16 Boehringer Ingelheim Int DPP4 inhibitors and pharmaceutical compositions comprising them, useful for treating metabolic diseases in pediatric patients, particularly type 2 diabetes mellitus
NZ594487A (en) 2009-02-13 2013-11-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
UY32427A (en) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh pharmaceutical composition, pharmaceutical form, process for their preparation, methods of treatment and uses thereof
JP2012517977A (en) * 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Antidiabetic agents including dpp-4 inhibitors (linagliptin) in combination with other antidiabetic agents optionally
PE02502012A1 (en) * 2009-02-13 2012-03-28 Boehringer Ingelheim Int pharmaceutical composition comprising diphenylmethane derivatives glucopyranosyl, pharmaceutical form thereof, process for their preparation
AR077859A1 (en) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compounds for the treatment of CNS disorders
CN102574829B (en) 2009-09-30 2015-07-01 贝林格尔.英格海姆国际有限公司 Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
BR112012007092A2 (en) 2009-09-30 2016-08-23 Boehringer Ingelheim Int Method for preparing a crystalline form of 1-chloro-4- (beta-D-glicopiranos-1-yl) -2- (4 - ((S) -tetraidrofuran-3-yloxy) benzyl) benzene
US20110236477A1 (en) * 2009-10-02 2011-09-29 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
BR112012007234A2 (en) * 2009-10-02 2016-04-05 Boehringer Ingelheim Int A pharmaceutical combination comprising a DPP-4 inhibitor and metformin, as well as its use and its preparation process
KR20170136017A (en) 2009-11-27 2017-12-08 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN102286011B (en) * 2010-03-16 2017-10-03 美德(江西)生物科技有限公司 Pyrrolidine boronate dipeptidyl peptidase inhibitors, and pharmaceutical compositions
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
MX2012012438A (en) 2010-05-05 2012-11-29 Boehringer Ingelheim Int Pharmaceutical formulations comprising pioglitazone and linagliptin.
EA201201508A1 (en) 2010-05-05 2013-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Combined therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
BR112013003097A2 (en) 2010-08-12 2016-06-28 Boehringer Ingelheim Int 6-cycloalkyl-pirazolopirimidemonas for the treatment of CNS disorders
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
AU2012204162B2 (en) 2011-01-07 2017-04-20 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
AU2012363873B2 (en) 2012-01-06 2017-11-23 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
EP2800562A2 (en) * 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
CN102617566B (en) * 2011-01-30 2015-03-04 山东轩竹医药科技有限公司 Pyrazolo alkylimidazole derivative
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2012118945A2 (en) * 2011-03-03 2012-09-07 Merck Sharp & Dohme Corp. Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP5876150B2 (en) 2011-07-15 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted quinazoline, use of these these preparation and pharmaceutical compositions
CN102362866A (en) * 2011-11-21 2012-02-29 郑飞雄 Medicinal composition for treating diabetes and obesity
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CA2867412A1 (en) * 2012-03-16 2013-09-19 Mona Wilcke Thiophene- based compounds exhibiting nox4 inhibitory activity and use thereof in therapy
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6374862B2 (en) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Autoimmune diabetes, in particular, xanthine derivatives as dpp-4 inhibitor for use in the treatment of lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20150246117A1 (en) 2012-09-24 2015-09-03 Ulf Eriksson Treatment of type 2 diabetes and related conditions
MX2015008077A (en) 2012-12-21 2015-10-30 Sanofi Sa Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists.
PL2978859T3 (en) 2013-03-27 2018-10-31 F.Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2014198906A1 (en) * 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for treating diabetes and its complications
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 Sanofi Sa Non-acylated EXENDIN-4 peptide analogues
EP3110449A1 (en) 2014-02-28 2017-01-04 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
TW201625670A (en) 2014-04-07 2016-07-16 Sanofi Sa Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 Sanofi Sa Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 Sanofi Sa Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa Exendin-4 derivatives as dual specific peptide agonists receptor glp-1 / glucagon
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof

Family Cites Families (750)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US2375138A (en) 1942-05-01 1945-05-01 American Cyanamid Co Alkamine esters of aryloxymethyl benzoic acid
US2629736A (en) 1951-02-24 1953-02-24 Searle & Co Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
US2730544A (en) 1952-07-23 1956-01-10 Sahyun Lab Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
US2750387A (en) 1953-11-25 1956-06-12 Searle & Co Basically substituted derivatives of diarylaminobenzamides
DE1211359B (en) 1955-11-29 1966-02-24 Oreal Oxydationsmittelfreies Kaltfaerbemittel for human hair
US2928833A (en) 1959-03-03 1960-03-15 S E Massengill Company Theophylline derivatives
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3673241A (en) 1968-04-04 1972-06-27 Ciba Geigy Corp Substituted benzaldehyde guanylhydrazones
ES385302A1 (en) 1970-10-22 1973-04-16 Miquel S A Lab Procedure for obtaining two trisubstitui- derivatives of ethylenediamine.
DE2205815A1 (en) 1972-02-08 1973-08-16 Hoechst Ag N-(oxazolin-2-yl)-piperazine - with antitussive activity
JPS5512435B2 (en) 1972-07-01 1980-04-02
US4005208A (en) 1975-05-16 1977-01-25 Smithkline Corporation N-Heterocyclic-9-xanthenylamines
US4061753A (en) 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
NO154918C (en) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate for preparing therapeutically active derivatives of 3,4,5-trihydroksypiperidin.
DE2758025A1 (en) 1977-12-24 1979-07-12 Bayer Ag Tri:hydroxy-piperidine derivs. - useful as glucosidase inhibitors for treating diabetes etc. and as animal feed additives
DE2929596A1 (en) 1979-07-21 1981-02-05 Hoechst Ag A process for preparing xanthines-oxoalkyl
CY1306A (en) 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
US4382091A (en) 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
JPH0130567Y2 (en) 1983-11-22 1989-09-19
FR2558162B1 (en) 1984-01-17 1986-04-25 Adir New xanthine derivatives, processes for their preparation and pharmaceutical compositions containing them
FI79107C (en) 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande Foer framstaellning of stabil -Form of prazosinhydroklorid.
JPH0531540B2 (en) 1984-07-23 1993-05-12 Shiseido Co Ltd
JPH0456591B2 (en) 1984-11-16 1992-09-08 Unitika Ltd
AR240698A1 (en) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
CA1242699A (en) 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
US4741898A (en) 1985-04-01 1988-05-03 Fisher Scientific Company Stabilized stain composition
US5258380A (en) 1985-06-24 1993-11-02 Janssen Pharmaceutica N.V. (4-piperidinylmethyl and -hetero)purines
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
DE3688827T2 (en) 1985-10-25 1994-03-31 Beecham Group Plc Piperidine derivative, its preparation and its use as a drug.
US5034225A (en) 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
DE3683760D1 (en) 1986-03-21 1992-03-12 Heumann Pharma Gmbh & Co Crystalline anhydrous sigma shape of 2- (4- (2-furoyl (2-piperazin) -1-yl) -4-amino-6,7-dimethoxyquinazoline hydrochloride, and processes for their preparation.
CA1341320C (en) 1986-05-05 2001-11-20 Joel Habener Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPS6440433A (en) 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
US5234897A (en) 1989-03-15 1993-08-10 Bayer Aktiengesellschaft Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
KR940000368B1 (en) 1988-05-19 1994-01-19 사노 하지메 Novel quinolone carboxylic acid derivatives
ES2070142T3 (en) 1988-05-19 1995-06-01 Chugai Pharmaceutical Co Ltd New quinolonecarboxylic acid derivatives.
US5329025A (en) 1988-09-21 1994-07-12 G. D. Searle & Co. 3-azido compound
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE3916430A1 (en) 1989-05-20 1990-11-22 Bayer Ag A process for the preparation of 3-amino-5-aminocarbonyl-1,2,4-triazol-derivatives
US5223499A (en) 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Method pharmaceutically usable / R- (R *, R *) / - 2- (4-fluorophenyl) - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - / (phenylamino) carbonyl / -1 pyrrole-1-heptanoic acid and pharmaceutically acceptable salts thereof
DE3926119A1 (en) 1989-08-08 1991-02-14 Bayer Ag 3-amino-5-aminocarbonyl-1,2,4-triazole derivatives
HU208115B (en) 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
FR2654935B1 (en) 1989-11-28 1994-07-01 Lvmh Rech Use of xanthines, optionally incorporated into liposomes, for promoting the pigmentation of the skin or hair.
AT134624T (en) 1990-02-19 1996-03-15 Ciba Geigy Ag acyl compounds
KR930000861B1 (en) 1990-02-27 1993-02-08 임성기 Omeprazole rectal composition
EP0475482B1 (en) 1990-09-13 1994-10-05 Akzo Nobel N.V. Stabilized solid chemical compositions
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5084460A (en) 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
US5602127A (en) 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5594003A (en) 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
DE4124150A1 (en) 1991-07-20 1993-01-21 Bayer Ag substituted triazoles
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5300298A (en) 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
EP0581552B1 (en) 1992-07-31 1998-04-22 SHIONOGI & CO., LTD. Triazolylthiomethylthio cephalosporin hyrochloride, its crystalline hydrate and the production of the same
TW252044B (en) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
DE4242459A1 (en) 1992-12-16 1994-06-23 Merck Patent Gmbh Imidazopyridines
US5624926A (en) 1993-02-18 1997-04-29 Kyowa Hakko Kogyo Co., Ltd. Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
JP3726291B2 (en) 1993-07-05 2005-12-14 三菱ウェルファーマ株式会社 Benzoxazine compound having a stable crystal structure and their preparation
FR2707641B1 (en) 1993-07-16 1995-08-25 Fournier Ind & Sante Compounds of the imidazol-5-carboxamide, process for their preparation intermediates thereof and their use in therapy.
DE4339868A1 (en) 1993-11-23 1995-05-24 Merck Patent Gmbh imidazopyridazines
DE4404183A1 (en) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-amino-1-piperidylbenzoylguanidine
US5545745A (en) 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
CO4410190A1 (en) 1994-09-19 1997-01-09 Lilly Co Eli 3- [4- (2-aminoethoxy) -benzoyl] -2-ARYL-6-hydroxybenzo [b] thiophene CRYSTALLINE
KR100237962B1 (en) 1994-10-12 2000-02-01 그린 마틴 Novel benzoxazoles
GB9501178D0 (en) 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
EP0825993A1 (en) 1995-05-19 1998-03-04 Chiroscience Limited Xanthines and their therapeutic use
DE69522718D1 (en) 1995-06-06 2001-10-18 Pfizer Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren
WO1996039384A1 (en) 1995-06-06 1996-12-12 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
JPH08333339A (en) 1995-06-08 1996-12-17 Fujisawa Pharmaceut Co Ltd Production of optically active piperidineacetic acid derivative
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19543478A1 (en) 1995-11-22 1997-05-28 Bayer Ag Crystalline hydrochloride of {(R) - (-) - [4- (1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl) -buytl] 2- N- aminomethyl} chroman
FR2742751B1 (en) 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa New taxoids, their preparation and pharmaceutical compositions containing them
NZ326238A (en) 1995-12-26 1999-11-29 Alteon Inc Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
US5891855A (en) * 1996-02-12 1999-04-06 The Scripps Research Institute Inhibitors of leaderless protein export
DE19616486C5 (en) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust A method for lowering blood glucose levels in mammals
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5965555A (en) 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
US5958951A (en) 1996-06-14 1999-09-28 Novo Nordiskials Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
ID21924A (en) 1996-09-23 1999-08-12 Lilly Co Eli Olanzapine dihydrate D
JP2001502703A (en) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ (-) - 3,4-trans - process for the preparation of diaryl chromans
US6191102B1 (en) 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
JP2001504105A (en) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Use of Glp-1 peptide
GB9623859D0 (en) 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
JP4878664B2 (en) 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド Stable liquid interferon formulation
DE19705233A1 (en) 1997-02-12 1998-08-13 Froelich Juergen C Preparation of stable, orally administered arginine solutions
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag Phthalazines, pharmaceutical preparations comprising them and process for their preparation
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
BR9808581A (en) 1997-03-13 2000-05-30 Hexal Ag Stabilization sensitive to benzimidazoles with amino acid / cyclodextrin combinations
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
CO4750643A1 (en) 1997-06-13 1999-03-31 Lilly Co Eli Stable insulin formulation containing L-arginine and protamine
EE200000318A (en) 1997-12-05 2001-08-15 Astrazeneca Uk Limited novel compounds
TW589174B (en) 1997-12-10 2004-06-01 Takeda Chemical Industries Ltd Agent for treating high-risk impaired glucose tolerance
JPH11193270A (en) 1997-12-26 1999-07-21 Koei Chem Co Ltd Production of optically active 1-methyl-3-piperidinemethanol
US6579868B1 (en) 1998-01-05 2003-06-17 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
ES2288807T1 (en) 1998-02-02 2008-02-01 1149336 Ontario Inc. Using dipeptidase inhibitors to regulate glucose metabolism.
US5998463A (en) 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
JP2002509919A (en) 1998-03-31 2002-04-02 日産化学工業株式会社 Pyridazinone compounds hydrochloride and its preparation
CA2268621A1 (en) 1998-04-13 1999-10-13 Takeda Chemical Industries, Ltd. 2-pipirazinone-1-acetic acid derivative, production and use thereof
US6207207B1 (en) 1998-05-01 2001-03-27 Mars, Incorporated Coated confectionery having a crispy starch based center and method of preparation
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Prodrugs of unstable inhibitors of dipeptidyl peptidase IV
EP0978279A1 (en) 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag Compounds n- (substituted glycyl) -2-cyanopyrrolidines inhibitors of dipeptidyl peptidase-IV (DPP-IV) which are effective in treating conditions mediated by DPP-IV
IT1312018B1 (en) 1999-03-19 2002-04-04 Fassi Aldo The improved process for the production of salts not igroscopicidella the (-) - carnitine.
BR0009486B1 (en) 1999-03-29 2011-03-09 comprising an amide compound, pharmaceutical composition comprising such a compound, its use and process for preparing the same.
EP1177797A1 (en) 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Novel use
US20040152659A1 (en) 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
WO2000072799A2 (en) 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
CN100448482C (en) 1999-05-31 2009-01-07 三菱化学株式会社 Freeze dried HGF preparations
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
AT271922T (en) 1999-06-01 2004-08-15 Elan Pharma Int Ltd Small mill and process for
PT1731511E (en) 1999-06-21 2015-11-13 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2166270B1 (en) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa I derivatives of 8-phenyl-6,9-dihydro- (1,2,4) triazolo (3,4-i) purin-5-one.
PT1213296E (en) 1999-08-31 2004-08-31 Kissei Pharmaceutical Derivatives of glucopiranosiloxipirazole medical compositions that contain them and intermediaries in their production
EP1220832A1 (en) 1999-09-29 2002-07-10 Novo Nordisk A/S Novel aromatic compounds
ES2211454T3 (en) 1999-09-30 2004-07-16 Pfizer Products Inc. Pyrrolyl phosphorylase inhibitors as collagen.
EP1391460A1 (en) 1999-09-30 2004-02-25 Pfizer Products Inc. Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors
PH12000002657B1 (en) 1999-10-12 2006-02-21 Squibb Bristol Myers Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
JP2003518496A (en) 1999-12-23 2003-06-10 ノバルティス アクチエンゲゼルシャフト The use of hypoglycemic drugs for the treatment of glucose metabolism disorders
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
CA2673615C (en) 2000-01-21 2013-07-16 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
CO5271699A1 (en) 2000-01-24 2003-04-30 Pfizer Prod Inc Process for the treatment of cardiomyopathy using glycogen phosphorylase inhibitors
JP4621326B2 (en) 2000-02-01 2011-01-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Stabilizing composition of teprenone
AU782878B2 (en) 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
EP1295609A4 (en) 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd Drugs containing combined active ingredients
EP1132389A1 (en) 2000-03-06 2001-09-12 F. Hoffmann-La Roche Ag New aza-indolyl derivatives for the treatment of obesity
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
DE60115623T2 (en) 2000-03-17 2006-07-06 Kissei Pharmaceutical Co., Ltd., Matsumoto Glucopyranosyloxy-benzylbenzen derivatives, medicinal composition and intermediates for the manufacture of derivatives
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
JP2001278812A (en) 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd Disintegrant for tablet and tablet using the same
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
AU4458401A (en) 2000-03-31 2001-10-15 Kirin Brewery Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
EP2266665B1 (en) * 2000-03-31 2016-05-11 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
JP2001292388A (en) 2000-04-05 2001-10-19 Sharp Corp Reproducing device
GB0008694D0 (en) 2000-04-07 2000-05-31 Novartis Ag Organic compounds
BR0110573A (en) 2000-05-03 2003-04-01 Hoffmann La Roche The compound, pharmaceutical composition comprising such a compound, a process for the preparation of a pharmaceutical composition, process and use of the compound for prophylactic or therapeutic treatment and for preparing the compound
CA2407428C (en) 2000-05-03 2010-02-02 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
AU778036B2 (en) 2000-05-08 2004-11-11 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
AT398611T (en) 2000-05-08 2008-07-15 Hoffmann La Roche Para-amine substituted phenylamide GK activators
SE0001899D0 (en) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AT265424T (en) 2000-06-09 2004-05-15 Aventis Pharma Gmbh Acylphenylharnstoffderivate, methods for their manufacture and their use as medicines
WO2001096301A1 (en) 2000-06-14 2001-12-20 Toray Industries, Inc. Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
WO2002002560A2 (en) 2000-07-04 2002-01-10 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
EP1305301B1 (en) 2000-07-20 2005-06-15 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
EP1308439B1 (en) 2000-08-10 2008-10-15 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
GB0021831D0 (en) 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ES2269456T3 (en) 2000-09-29 2007-04-01 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same.
ES2337127T3 (en) 2000-11-02 2010-04-21 Ajinomoto Co., Inc. New pyrazole derivatives and diabetes remedies that contain them.
US20060034922A1 (en) 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
WO2003047626A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
JP4212891B2 (en) 2000-11-30 2009-01-21 キッセイ薬品工業株式会社 Glucopyranosyloxy benzyl benzene derivatives, pharmaceutical compositions and their preparation intermediates containing the same
BR0115999A (en) 2000-12-06 2003-09-30 Hoffmann La Roche The compound, pharmaceutical composition comprising it, its use, method for the prophylactic or therapeutic treatment of type II diabetes and process for preparing the compound
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
RU2317302C2 (en) 2000-12-28 2008-02-20 Киссеи Фармасьютикал Ко., Лтд. Derivatives of glucopyranosyloxypyrazole and their using in medicinal agents
FR2818906B1 (en) 2000-12-29 2004-04-02 Dospharma drug combination of a biguanide and a carrier, for example metformin and arginine
FR2819254B1 (en) 2001-01-08 2003-04-18 Fournier Lab Sa New compounds of the N- (phenylsulfonyl) glycine, their method of preparing and using them to obtain pharmaceutical compositions
US7034039B2 (en) 2001-02-02 2006-04-25 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US7610153B2 (en) 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US6649187B2 (en) 2001-02-16 2003-11-18 Bristol-Myers Squibb Pharma Company Use of polyalkylamine polymers in controlled release devices
SI1757606T1 (en) 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Xanthinderivatives for use as medical agents and the preparation thereof
DE10109021A1 (en) 2001-02-24 2002-09-05 Boehringer Ingelheim Pharma New 8-substituted-xanthine derivatives, useful e.g. for treating diabetes and arthritis, act by inhibiting dipeptidylpeptidase-IV
DE60230591D1 (en) 2001-02-26 2009-02-12 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate and their medical use
EP1364958B1 (en) 2001-02-27 2010-09-08 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6693094B2 (en) 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
DE10117803A1 (en) 2001-04-10 2002-10-24 Boehringer Ingelheim Pharma New 8-substituted-xanthine derivatives, useful e.g. for treating diabetes and arthritis, act by inhibiting dipeptidylpeptidase-IV
ES2258141T3 (en) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Amino acid complexes of c-aryl for the treatment of diabetes and procedure glucosides.
WO2002088157A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazolyl-o-glycoside derivatives and remedial agent for diabetes containing the same
PE10912002A1 (en) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Phenylurea derivatives substituted carbonamide and process for its preparation
JP2002348279A (en) 2001-05-25 2002-12-04 Nippon Kayaku Co Ltd Production method for optically active pyridylketone derivatives and optically active pyridylketone derivatives
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
BR0210510A (en) 2001-06-20 2005-01-11 Kissei Pharmaceutical nitrogen-containing heterocyclic derivative, medicinal composition containing the same, and medical use thereof for the same intermediate
DE10130371A1 (en) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
SE0102300D0 (en) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (en) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
JP4357293B2 (en) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション Dipeptidyl peptidase-fluoro pyrrolidines as peptidase inhibitors
HU0400321A2 (en) 2001-06-27 2004-08-30 Smithkline Beecham Corp. Fluoropyrrolidine derivatives as dipeptidyl-dipeptidase inhibitors, and pharmaceutical compositions containing them
JP4115105B2 (en) 2001-07-02 2008-07-09 協和醗酵工業株式会社 Pyrazole derivatives
EP1404675B1 (en) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
AR036114A1 (en) 2001-07-06 2004-08-11 Merck & Co Inc Tetrahydroimidazol [1,2-a] pyrazines and tetrahidrotriazol [4,3-a] pyrazines are as inhibitors of dipeptidyl peptidase useful for the treatment or prevention of diabetes
MXPA04000224A (en) 2001-07-10 2005-07-25 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
JPWO2003011880A1 (en) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 Glucopyranosyloxy benzyl benzene derivatives, pharmaceutical compositions containing them, their pharmaceutical use and its production intermediate
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
AU2002331311A1 (en) 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
IL161335D0 (en) 2001-10-15 2004-09-27 Hemoteq Gmbh Coating of stents for preventing restenosis
DE10151296A1 (en) 2001-10-17 2003-04-30 Boehringer Ingelheim Pharma Keratinocytes used as biologically active substance in the treatment of wounds
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030083354A1 (en) 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
EP1452526A1 (en) 2001-10-29 2004-09-01 Japan Tobacco Inc. Indole compound and medicinal use thereof
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
PL370275A1 (en) 2001-11-22 2005-05-16 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04004842A (en) 2001-11-22 2004-08-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
KR20050044577A (en) 2001-11-22 2005-05-12 바이오비트럼 에이비 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2002360453C1 (en) 2001-11-26 2009-06-18 The Brigham And Women's Hospital, Inc. Methods for treating autoimmune disorders, and reagents related thereto
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2003053929A1 (en) 2001-12-21 2003-07-03 Toray Fine Chemicals Co., Ltd. Process for production of optically active cis-piperidine derivatives
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US20070197552A1 (en) 2002-01-11 2007-08-23 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
EP1496877B1 (en) 2002-01-11 2008-10-01 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
DK1467712T4 (en) 2002-01-16 2011-11-21 Boehringer Ingelheim Pharma A method for producing a bilayer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide
MXPA04006937A (en) 2002-01-18 2004-12-06 Pfizer Prod Inc Intermediates for preparing glycogen phosphorylase inhibitors.
EP1333033A1 (en) 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
US7329683B2 (en) 2002-02-01 2008-02-12 Merck & Co., Inc. 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
PL373914A1 (en) 2002-02-01 2005-09-19 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
AT536173T (en) 2002-02-21 2011-12-15 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol
DE60304911D1 (en) 2002-02-25 2006-06-08 Eisai Co Ltd Xanthine derivatives as DPP-IV inhibitors
MXPA03000966A (en) 2002-02-28 2003-09-04 Pfizer Prod Inc Antidiabetic agents.
HU0200849A2 (en) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetyl-2-cyano-pyrrolidine derivatives, and pharmaceutical compositions containing these compounds preparation process
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
JP4490109B2 (en) 2002-03-22 2010-06-23 キッセイ薬品工業株式会社 Crystals glucopyranosyloxy benzyl benzene derivatives
MXPA05009564A (en) 2003-03-12 2005-11-17 Univ Arizona Weak base salts.
JP4419571B2 (en) 2002-03-26 2010-02-24 萬有製薬株式会社 New aminobenzamide derivative
JP4298212B2 (en) 2002-03-29 2009-07-15 大日本印刷株式会社 Preparation of epinastine hydrochloride high melting point type crystal
JP2003300977A (en) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd Xanthine derivatives
DE10215907A1 (en) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl urea derivatives, processes for their preparation and their use
DE10215908B4 (en) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl urea derivatives and their use as medicaments
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
US20050113577A1 (en) 2002-04-16 2005-05-26 Karki Shyam B. Solid forms of slats with tyrosine kinase activity
JPWO2003091213A1 (en) 2002-04-25 2005-09-02 アステラス製薬株式会社 Novel amide derivative or a salt thereof
WO2003090783A1 (en) 2002-04-26 2003-11-06 Ajinomoto Co., Inc. Preventive/remedy for diabetes
AT346056T (en) 2002-04-26 2006-12-15 Hoffmann La Roche phenylacetamides substituted and their use as glucokinase activators
WO2003094909A2 (en) 2002-05-09 2003-11-20 Enos Pharmaceuticals, Inc. Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
GB2388594A (en) * 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP2005529934A (en) 2002-05-31 2005-10-06 シェーリング コーポレイションSchering Corporation Xanthine phosphodiesterase v inhibitors and processes for preparing the precursor
CN100469778C (en) 2002-06-06 2009-03-18 卫材R&D管理有限公司 Novel fused imidazole derivative
DE10225635C1 (en) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido acid derivatives, processes for their preparation and their use
AR040241A1 (en) 2002-06-10 2005-03-23 Merck & Co Inc Inhibitors hydroxysteroid 11-beta-deshidrogrenasa 1 for the treatment of obesity and diabetes dyslipidaemia
ES2199061B1 (en) 2002-06-10 2005-02-16 Laboratorios Vita, S.A. orodispersible tablets and process for their preparation.
FR2840897B1 (en) 2002-06-14 2004-09-10 Fournier Lab Sa New derivatives of arylsulfonamides and their use in therapeutic
PL215132B1 (en) 2002-06-27 2013-10-31 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US20040002615A1 (en) 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
BR0312593A (en) 2002-07-11 2005-04-12 Aventis Pharma Gmbh Acylureas replaced by urea and urethane, process for its production and its application
KR20050025345A (en) 2002-07-12 2005-03-14 아벤티스 파마 도이칠란트 게엠베하 Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US20040023981A1 (en) 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
KR20050025189A (en) 2002-07-27 2005-03-11 아스트라제네카 아베 Chemical compounds
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
CA2494179C (en) 2002-08-08 2012-04-24 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
PL372865A1 (en) 2002-08-09 2005-08-08 Taisho Pharmaceutical Co, Ltd. Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
SI1532149T1 (en) 2002-08-21 2010-05-31 Boehringer Ingelheim Pharma 8-?á3-AMINO-PIPERIDIN-1-YL?å-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238243A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity
DE10238477A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, their preparation and their use as medicaments
DE10238470A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their preparation and their use as medicaments
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
JP2004137245A (en) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd Pyrazole derivative, pharmaceutical composition containing the same, its pharmaceutical use and production intermediate
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituted Pyrazolyprimidine
DE10238724A1 (en) 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
AU2003262262A1 (en) 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
WO2004024184A1 (en) 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited Sustained release preparation
US20040126358A1 (en) 2002-09-16 2004-07-01 Warne Nicholas W. Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
WO2004028524A1 (en) 2002-09-26 2004-04-08 Eisai Co., Ltd. Combination drug
MXPA05003391A (en) 2002-10-03 2005-06-22 Hoffmann La Roche Indole-3-carboxamides as glucokinase (gk) activators.
EP1549626A1 (en) 2002-10-03 2005-07-06 Novartis AG Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
DE10246434B4 (en) 2002-10-04 2005-08-04 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituted acyl-carboxyphenyl urea derivatives and their use as medicaments
AU2003267732A1 (en) 2002-10-08 2004-05-04 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004033455A2 (en) 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US20040122048A1 (en) 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
WO2004033427A1 (en) 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
UA78612C2 (en) 2002-10-18 2007-04-10 Merck & Co Inc Dipeptidylpeptidase-iv inhibitors for treatment or prevention of diseases
JP2006514614A (en) 2002-10-24 2006-05-11 ステリックス リミテッド 11β- hydroxysteroid dehydrogenase type 1 and type 2 inhibitor
JP2004161749A (en) 2002-10-24 2004-06-10 Toray Fine Chemicals Co Ltd Method for producing optically active, nitrogen-containing compound
AU2003273762A1 (en) 2002-10-28 2004-05-13 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2003280680A1 (en) 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
MXPA05004890A (en) 2002-11-07 2005-07-22 Merck & Co Inc Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes.
JP2006514102A (en) 2002-11-07 2006-04-27 アストラゼネカ アクチボラグ 2-oxo - ethanesulfonamide derivatives
AU2003274462A1 (en) 2002-11-07 2004-06-07 Pfizer Products Inc. N-(indole-2-carbonyl) amides as anti-diabetic agents
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (en) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity
DE10254304A1 (en) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their preparation and their use as medicaments
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (en) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma New imidazo-pyridinones substituted, their preparation and their use as medicacmentos
JP4651934B2 (en) 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 Benzyl phenol derivatives, pharmaceutical compositions containing them and their pharmaceutical use
BR0317028A (en) 2002-12-10 2005-10-25 Novartis Ag A combination of a DPP-IV is a compound of PPAR-alpha
DE10258007B4 (en) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatic Fluorglycosidderivate, containing these compounds, pharmaceutical compositions and methods for producing these drug
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
DE10258008B4 (en) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh , Pharmaceuticals containing these compounds and methods for preparing heterocyclic Fluorglycosidderivate these drugs
JP2004196702A (en) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd Novel amide derivative or its salt
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
DE10351663A1 (en) 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Stable, accurately dosable inhalable powder medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium, specific form of salmeterol xinafoate and auxiliary
US20040152720A1 (en) 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
JP4679155B2 (en) 2002-12-25 2011-04-27 キッセイ薬品工業株式会社 Nitrogen-containing heterocyclic derivatives, pharmaceutical compositions containing them and their pharmaceutical use
CA2509086C (en) 2003-01-06 2012-08-21 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2004063194A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
SI1599222T1 (en) 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
MXPA05007485A (en) 2003-01-14 2006-01-30 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia.
DE10302452B4 (en) 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituted acyl-phenyl-urea derivatives, processes for their preparation and their use
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
PL378117A1 (en) 2003-02-11 2006-03-06 Prosidion Limited Tri(cyclo) substituted amide compounds
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
CA2515841C (en) 2003-02-13 2010-06-01 Banyu Pharmaceutical Co., Ltd. Novel 2-pyridine carboxamide derivatives
PE09502004A1 (en) 2003-02-14 2005-01-01 Theravance Inc Biphenyl derivatives as agonists beta2 adrenoceptor antagonists RECEIVERS AND muscarinic receptor
DE10306502B4 (en) 2003-02-17 2005-03-17 Aventis Pharma Deutschland Gmbh Substituted 3- (Benzoylureido) -thiophenderivate and pharmaceutical compositions containing them
JP2004250336A (en) 2003-02-18 2004-09-09 Kao Corp Method for producing coated tablet and sugar-coated tablet
JP4432901B2 (en) 2003-02-26 2010-03-17 萬有製薬株式会社 Heteroaryl arylcarbamoyl benzene derivatives
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
DE10309929B4 (en) 2003-03-07 2006-02-23 Sanofi-Aventis Deutschland Gmbh Benzoylureidopyridyl substituted-piperidine and -pyrrolidine carboxylic acid derivatives, processes for their preparation and their use
ES2363941T3 (en) 2003-03-14 2011-08-19 Astellas Pharma Inc. I c-glucoside derivatives for treating diabetes.
CN100415224C (en) 2003-03-18 2008-09-03 诺瓦提斯公司 Compositions comprising fatty acids and amino acids
WO2005016365A2 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP2004300102A (en) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd Condensed heterocyclic derivative, pharmaceutical composition containing the same and its pharmaceutical application
WO2004089967A1 (en) 2003-04-01 2004-10-21 Taisho Pharmaceutical Co., Ltd. HETEROARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME
EP1615646B1 (en) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
EP1615647B1 (en) 2003-04-11 2010-01-20 High Point Pharmaceuticals, LLC Pharmaceutical use of fused 1,2,4-triazoles
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
JP2006522745A (en) 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブNovo Nordisk Aktie Selsxab Pharmaceutical use of substituted 1,2,4-triazole
BRPI0409465A (en) 2003-04-17 2006-05-02 Pfizer Prod Inc carboxamide derivatives as antidiabetic agents
WO2004096768A1 (en) 2003-04-30 2004-11-11 Pfizer Products Inc. Anti-diabetic agents
JPWO2004096806A1 (en) 2003-04-30 2006-07-13 大日本住友製薬株式会社 Fused imidazole derivatives
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
AT473974T (en) 2003-05-21 2010-07-15 Prosidion Ltd Pyrrolopyridine-2-carboxylic acids as inhibitors of glycogen phosphorylase
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
CN1795181A (en) 2003-05-29 2006-06-28 麦克公司 Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
AU2003902828A0 (en) 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
JP2004359630A (en) 2003-06-06 2004-12-24 Kotobuki Seiyaku Kk Difluorodiphenylmethane derivative and its salt
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10327439A1 (en) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New Imidazopyridazinon- and Imidazopyridonderivate, their preparation and their use as medicaments
WO2004113345A1 (en) 2003-06-20 2004-12-29 Japan Tobacco Inc. Fused pyrrole compound and medicinal use thereof
CA2529878C (en) 2003-06-20 2012-11-20 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
NZ543863A (en) 2003-06-20 2009-05-31 Hoffmann La Roche Hexahydropyridoisoquinolines as DPP-IV inhibitors
CA2529443C (en) 2003-06-20 2012-06-05 F. Hoffmann-La Roche Ag Pyrido[2,1-a]-isoquinoline derivatives as dpp-iv inhibitors
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc Aryl and heteroaryl derivatives as modulators of metabolism trisubstituted and the prophylaxis and treatment of disorders related thereto
CA2532971A1 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20050027012A1 (en) 2003-07-16 2005-02-03 Boehringer Ingelheim International Gmbh Tablets containing ambroxol
US20060134206A1 (en) 2003-07-24 2006-06-22 Iyer Eswaran K Oral compositions for treatment of diseases
DE10335027A1 (en) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
DE10335092B3 (en) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Benzoylureido substituted-o-benzoylamide, processes for their preparation and their use
DK1651658T3 (en) 2003-08-01 2013-02-18 Mitsubishi Tanabe Pharma Corp Novel compounds having inhibitory activity against sodium-dependent transporter
EP1679965A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
WO2005012242A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
AR048282A1 (en) 2003-08-01 2006-04-19 Janssen Pharmaceutica Nv Indole or - substituted glucosides
AR053329A1 (en) 2005-01-31 2007-05-02 Tanabe Seiyaku Co Indole derivatives useful as inhibitors of glucose transporters sodium-dependent (SGLT)
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
TW200517381A (en) 2003-08-01 2005-06-01 Genelabs Tech Inc Bicyclic heteroaryl derivatives
CA2549017A1 (en) 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
JP2007501789A (en) 2003-08-07 2007-02-01 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated 11-beta-pyrazolecarboxamide as inhibitors of hydroxysteroid dehydrogenases -1
GB0318463D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318464D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
DE502004008951D1 (en) 2003-08-26 2009-03-19 Boehringer Ingelheim Pharma Glucopyranosyloxy-pyrazoles containing these compounds drug whose use and process for their manufacture
WO2005020985A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005023179A2 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
WO2005020986A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
JP2007505121A (en) 2003-09-08 2007-03-08 武田薬品工業株式会社 Dipeptidyl peptidase inhibitors
AT534404T (en) 2003-10-03 2011-12-15 Takeda Pharmaceutical Dipeptidyl peptidase IV inhibitors for the treatment of diabetic patients with secondary failure by sulfonylureas
US7284625B2 (en) 2003-10-22 2007-10-23 Kirk Jones Quick connect assembly for ATV implements
EP1675844A1 (en) 2003-10-23 2006-07-05 Sterix Limited Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase
US20050091394A1 (en) 2003-10-27 2005-04-28 Schneider Automation Inc. Software configurable dual cable redundant Ethernet or bus configuration
CA2543602A1 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
US7246174B2 (en) 2003-10-28 2007-07-17 Nacon Consulting, Llc Method and system for accessing and managing virtual machines
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
WO2005049022A2 (en) * 2003-11-17 2005-06-02 Novartis Ag Use of dipeptidyl peptidase iv inhibitors
JP2005170939A (en) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd Prophylactic/therapeutic agent for diabetes
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
DE10355304A1 (en) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8- (piperazin-1-yl) -and 8 - ([1,4] diazepan-1-yl) -xanthines, their preparation and their use as medicaments
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
JPWO2005053695A1 (en) 2003-12-04 2007-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Multiple sclerosis prophylactic or therapeutic agents
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
DE10359098A1 (en) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2- (piperazin-1-yl) - and 2 - ([1,4] diazepan-1-yl) imidazo [4,5-d] pyridazin-4-ones, their preparation and their use as medicaments
US7217711B2 (en) 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
CA2548654C (en) 2003-12-18 2012-08-07 Tibotec Pharmaceuticals Ltd. Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
EP1696915A1 (en) 2003-12-19 2006-09-06 Pfizer, Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
DE10361133A1 (en) 2003-12-22 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyloxy-substituted aromatics medicines containing these compounds, their use and processes for their preparation
AU2004308932A1 (en) 2003-12-22 2005-07-14 Amgen Inc Aryl sulfonamide compounds and uses related thereto
DE10360835A1 (en) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
WO2005061489A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
JP4707560B2 (en) 2003-12-29 2011-06-22 Msd株式会社 Novel 2-heteroaryl substituted benzimidazole derivatives
MXPA06007715A (en) 2004-01-06 2007-01-26 Johnson & Johnson (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity.
PT1723128E (en) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaryl-ureas and their use as glucokinase activators
JP4994043B2 (en) 2004-01-21 2012-08-08 エランコ・アニマル・ヘルス・アイルランド・リミテッド Mitoratapide oral solution
CN1910161A (en) 2004-01-26 2007-02-07 默克公司 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
DE102004004971B3 (en) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, to processes for their preparation and their use as Arnzeimittel
WO2005073229A1 (en) 2004-01-31 2005-08-11 Sanofi-Aventis Deutschland Gmbh 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
DE102004004972B3 (en) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Heterocyclic-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, to processes for their preparation and their use as medicaments
JP2005247834A (en) 2004-02-04 2005-09-15 Taisho Pharmaceut Co Ltd Activity inhibitor of sodium-dependent glucose cotransporter 2
US20050239853A1 (en) 2004-02-04 2005-10-27 Tjeerd Barf New compounds
SE0400234D0 (en) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for Their preparation and use thereof
KR20070007104A (en) 2004-02-18 2007-01-12 아스트라제네카 아베 Compounds
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1718624B1 (en) 2004-02-18 2009-03-25 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents
CN102199151A (en) 2004-02-18 2011-09-28 贝林格尔.英格海姆国际有限公司 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use
DE102004009039A1 (en) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-amino-piperidin-1-yl] -xanthines, their preparation and use as medicaments
AU2005219777B2 (en) 2004-03-04 2011-02-03 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
CA2557766C (en) 2004-03-04 2013-02-05 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
JP4950657B2 (en) 2004-03-04 2012-06-13 キッセイ薬品工業株式会社 Fused heterocyclic derivatives, pharmaceutical compositions containing them and their pharmaceutical use
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
ES2353309T3 (en) 2004-03-08 2011-03-01 Prosidion Ltd. Hydrazides pyrrolopyridine-2-carboxylic acid as glycogen phosphorylase inhibitors.
WO2005085194A2 (en) 2004-03-08 2005-09-15 Prosidion Limited Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
MXPA06010571A (en) 2004-03-15 2007-02-16 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors.
EP1730131B1 (en) 2004-03-16 2012-05-09 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
EP1577306A1 (en) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases
US7354938B2 (en) 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd Substituted quinazoline or pyridopyrimidine derivative
CN1938286A (en) 2004-03-29 2007-03-28 默克公司 Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2005095373A1 (en) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
JPWO2005095372A1 (en) 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 Naphthalene derivatives, pharmaceutical compositions and pharmaceutical uses comprising the same
JPWO2005095429A1 (en) 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 Phenol derivatives, pharmaceutical compositions and pharmaceutical uses comprising the same
PT1735322E (en) 2004-04-02 2012-01-12 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful for the treatment of type 2 diabetes
KR20070006816A (en) 2004-04-02 2007-01-11 노파르티스 아게 Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
JP2007261945A (en) 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd Thiazole derivative
US7179809B2 (en) 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
EP1740589A1 (en) 2004-04-10 2007-01-10 Boehringer Ingelheim International GmbH Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments
US7402704B2 (en) 2004-04-14 2008-07-22 Amgen Inc. Arylsulfones and uses related thereto
MXPA06012143A (en) 2004-04-20 2007-05-15 Amgen Inc Arylsulfonamides and uses related thereto.
GB0408771D0 (en) 2004-04-20 2004-05-26 Sterix Ltd Compound
BRPI0510163A (en) 2004-04-21 2007-10-02 Prosidion Ltd Compounds of amides tri (cyclo) -substituted
DE102004019540A1 (en) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Composition, useful for treatment of e.g. inflammatory and obstructive respiratory complaint, sinus rhythm in heart in atrioventricular block and circulatory shock, comprises 6-hydroxy-4H-benzo1,4oxazin-3-one derivatives and other actives
US20050239778A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US20050244502A1 (en) 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
US20050261302A1 (en) 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20050245533A1 (en) 2004-04-29 2005-11-03 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application
US20050245534A1 (en) 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050245532A1 (en) 2004-04-29 2005-11-03 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
CN1976691B (en) * 2004-05-03 2010-10-13 奥加生物药业(I.P.3)有限公司 Cysteamines for treating complications of hypercholesterolemia and diabetes
BRPI0510623A (en) 2004-05-06 2007-10-30 Pfizer compounds and morpholine derivatives proline
ES2525319T3 (en) 2004-05-07 2014-12-22 Janssen Pharmaceutica Nv Derivatives pyrrolidin-2-one and piperidin-2-one derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase
ES2307175T3 (en) 2004-05-07 2008-11-16 Janssen Pharmaceutica Nv Derivatives adamantyl pyrrolidin-2-one derivatives as inhibitors dela 11-beta-hydroxysteroid dehydrogenase.
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
ES2327857T3 (en) 2004-05-12 2009-11-04 Pfizer Products Inc. Proline derivatives and their use as inhibitors of dipeptidyl peptidase IV.
DE102004024454A1 (en) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg New Enantiomerically pure beta-agonists, to processes for their preparation and their use as medicaments
AU2005247929B2 (en) 2004-05-24 2010-03-11 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PE03152006A1 (en) 2004-05-24 2006-05-15 Irm Llc Thiazole compounds as PPAR modulators
TWI354569B (en) 2004-05-28 2011-12-21 Squibb Bristol Myers Co Coated tablet formulation and method
US7858082B2 (en) 2004-06-01 2010-12-28 Ares Trading S.A. Method of stabilizing proteins
US7935723B2 (en) 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
WO2005120576A2 (en) * 2004-06-09 2005-12-22 Yasoo Health Composition and method for improving pancreatic islet cell survival
DE102004028241B4 (en) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh New fluoroglycoside pyrazoles, pharmaceutical compositions containing these compounds and manufacture of these drugs
JP2008504274A (en) 2004-06-24 2008-02-14 インサイト・コーポレイションIncyte Corporation Use as amide compounds and their pharmaceutically
BRPI0512535A (en) 2004-06-24 2008-03-25 Incyte Corp piperidines N-substituted compounds, their compositions and methods of modulations
WO2006002350A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
DE102004030502A1 (en) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg New imidazoles and triazoles, their preparation and use as medicaments
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20060009471A1 (en) 2004-06-24 2006-01-12 Wenqing Yao Amido compounds and their use as pharmaceuticals
NZ551859A (en) 2004-06-28 2010-05-28 Hoffmann La Roche Pyrimidine derivatives as 11beta-HSD1 inhibitors
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
US20080269311A1 (en) 2004-07-14 2008-10-30 Edwin Bernard Villhauer Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors
DE102004034690A1 (en) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methylidene-D-xylopyranosyl-D-xylopyranosyl and oxo-substituted phenyls medicaments containing these compounds, their use and processes for their preparation
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (en) 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
CN1020944C (en) 2004-07-27 1993-05-26 阿图尔-费希尔股份公司费希尔厂 Fastening element
DE602005008079D1 (en) 2004-07-28 2008-08-21 Hoffmann La Roche Aryl pyridine derivatives as 11-beta-HSD1 inhibitors
US20060025445A1 (en) 2004-08-02 2006-02-02 Xiang Jason S 11-Beta HSD1 inhibitors
JP2008509146A (en) 2004-08-06 2008-03-27 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated 11-beta - sulfonyl compounds as inhibitors of hydroxysteroid dehydrogenases -1
JP2006045156A (en) 2004-08-06 2006-02-16 Sumitomo Pharmaceut Co Ltd Condensed pyrazole derivative
WO2006020598A2 (en) 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006018150A1 (en) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituited cyclene, medicaments containing said compounds, use thereof and method for the production thereof
EP1789396A1 (en) 2004-08-12 2007-05-30 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
EP1782832A4 (en) 2004-08-26 2009-08-26 Takeda Pharmaceutical Remedy for diabetes
JP5137574B2 (en) 2004-08-30 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap Tricyclic lactam derivatives as 11-beta hydroxy steroid hydrogenase kinase inhibitor
WO2006024627A2 (en) 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE102004043944A1 (en) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as medicaments
DE102004044221A1 (en) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl-xanthine, their production and their use as medicaments
KR101214665B1 (en) 2004-09-16 2012-12-21 아스텔라스세이야쿠 가부시키가이샤 Triazole derivatives or salts thereof
JP4671648B2 (en) 2004-09-17 2011-04-20 株式会社ソニー・コンピュータエンタテインメント Repeater, entertainment device, a communication system, a communication method, and program
CN1759834B (en) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
CA2580461A1 (en) 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
AR051446A1 (en) 2004-09-23 2007-01-17 Squibb Bristol Myers Co C-glucosides aryl as selective inhibitors of glucose transporters (SGLT2)
WO2006035796A1 (en) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. 1-(β-D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF
DE102004048388A1 (en) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-pyranosyl-substituted phenyls, medicaments containing these compounds, their use and processes for their preparation
MX2007003913A (en) 2004-10-04 2007-05-21 Hoffmann La Roche Alkil-pyridines as 11-beta inhibitors for diabetes.
AU2005294320A1 (en) 2004-10-08 2006-04-20 Novartis Ag Combination of organic compounds
US8138342B2 (en) 2004-10-12 2012-03-20 High Point Pharmacueticals, LLC 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
AU2005293266B2 (en) 2004-10-12 2011-09-29 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
JP2008517921A (en) 2004-10-25 2008-05-29 ノバルティス アクチエンゲゼルシャフト Dpp-iv inhibitors, PPAR antidiabetic agent and metformin combination agent
EP1807072B1 (en) 2004-10-29 2009-01-07 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5036316B2 (en) 2004-11-02 2012-09-26 Msd株式会社 Aryloxy-substituted benzimidazole derivatives
JP2008518903A (en) 2004-11-02 2008-06-05 ファイザー・インク The novel compounds of substituted and unsubstituted adamantyl amide
DE102005013967A1 (en) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New imidazole or pyrimidine derivatives are bradykinin B1 antagonists used for treating e.g. pain, stroke, peptic ulcers and other inflammatory disorders
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg A process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
WO2006051662A1 (en) 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
CN101098852A (en) 2004-11-09 2008-01-02 史密丝克莱恩比彻姆公司 Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
CN102731499B (en) 2004-11-10 2016-01-13 因塞特控股公司 Lactam compounds and their use as medicaments
JP2006137678A (en) 2004-11-10 2006-06-01 Shionogi & Co Ltd Interleukin-2 composition
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055752A2 (en) 2004-11-18 2006-05-26 Incyte Corporation INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
EP1813611B1 (en) 2004-11-18 2014-10-01 Kissei Pharmaceutical Co., Ltd. 1-substituted-3- beta-d-glycopyranosylated nitrogenous hetero- cyclic compounds and medicines containing the same
GB0425919D0 (en) 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
US20090099176A1 (en) 2004-12-02 2009-04-16 Thomas Martin Krulle Pyrrolopyridine-2-carboxylic acid amides
WO2006059163A1 (en) 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DK1819704T3 (en) 2004-12-02 2008-10-20 Prosidion Ltd Pyrrolopyridine-2-carboxylic acid amide derivative useful as an inhibitor of glycogen phosphorylase
JP2008521864A (en) 2004-12-03 2008-06-26 トランステック・ファーマ、インコーポレイテッドTransTech Pharma, Inc. Heteroaromatic glucokinase activators
JP2008007405A (en) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd Carboxamide derivative
ES2314743T3 (en) 2004-12-16 2009-03-16 Boehringer Ingelheim International Gmbh Substituted benzene derivatives glucopyranosyl, to medicaments containing these compounds, their use and process for their manufacture.
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
ES2308602T3 (en) 2004-12-20 2008-12-01 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1.
ES2308601T3 (en) 2004-12-21 2008-12-01 Eli Lilly And Company Lactam derivatives as inhibitors cycloalkyl-11-beta-hydroxysteroid dehydrogenase 1 '.
WO2006068199A1 (en) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. Metabolically stable 3-oxy-1,2,4-triazole derivatives
JPWO2006068163A1 (en) 2004-12-24 2008-06-12 大日本住友製薬株式会社 Bicyclic pyrrole derivatives
KR100760430B1 (en) 2004-12-31 2007-10-04 한미약품 주식회사 Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
CN102816081A (en) 2005-01-05 2012-12-12 雅培制药有限公司 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
AT555081T (en) 2005-01-05 2012-05-15 Abbott Lab Adamantyl derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 enzyme
US20060148871A1 (en) 2005-01-05 2006-07-06 Rohde Jeffrey J Metabolic stabilization of substituted adamantane
TWI374882B (en) 2005-01-07 2012-10-21 Taisho Pharma Co Ltd
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc combination therapy for treating diabetes and related conditions and for the treatment of conditions ameliorated by an increase in the blood concentration of glp-1
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
GT200600008A (en) 2005-01-18 2006-08-09 Direct compression formulation and process
TWI377211B (en) 2005-01-28 2012-11-21 Chugai Pharmaceutical Co Ltd
WO2006080533A1 (en) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. 3-amino-1,2,4-triazole derivative
US20090124682A1 (en) 2005-02-05 2009-05-14 Alan Martin Birch Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity
CA2595835A1 (en) 2005-02-05 2006-08-10 Astrazeneca Ab Chemical compounds
WO2006087997A1 (en) 2005-02-15 2006-08-24 Kissei Pharmaceutical Co., Ltd. 1-SUBSTITUTED-7-(β-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME
BRPI0609062A2 (en) 2005-03-03 2010-02-17 F Hoffmann-La Roche Ag pharmaceutical composition, compound, method for the therapeutic and / or prophylactic treatment of diseases which are modulated by hydroxysteroid dehydrogenase inhibitors, 11ff and use of compounds
WO2006095822A1 (en) 2005-03-11 2006-09-14 Ono Pharmaceutical Co., Ltd. Sulfonamide compound and pharmaceutical thereof
US20080153791A1 (en) 2005-03-18 2008-06-26 Onpharm Gmbh 11Beta -Hydroxysteroid Dehydrogenases
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
WO2006104280A1 (en) 2005-03-31 2006-10-05 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for diabetes
JP5140577B2 (en) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド Hydroxysteroid dehydrogenase inhibitor
BRPI0610459A2 (en) 2005-04-05 2010-06-22 Hoffmann La Roche compound, process for their preparation, pharmaceutical compositions comprising it, a method for the therapeutic and / or prophylactic treatment of diseases which are modulated by hydroxysteroid dehydrogenase inhibitors, 11b and using the compound
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
AT453656T (en) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituted (heteroaryloxy-benzyl) -benzene derivatives as SGLT inhibitors
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2006111169A1 (en) 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
AU2006239929B2 (en) 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
US7898255B2 (en) 2005-04-25 2011-03-01 Hitachi, Ltd. Inspection apparatus using magnetic resonance and nuclear magnetic resonance signal receiver coil
US7713938B2 (en) 2005-05-03 2010-05-11 Boehringer Ingelheim International Gmbh Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
WO2006126695A1 (en) 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
WO2006125958A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
KR20080016671A (en) 2005-05-25 2008-02-21 와이어쓰 Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP1894919B1 (en) 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
WO2006132436A1 (en) 2005-06-08 2006-12-14 Japan Tobacco Inc. Heterocyclic compound
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
GT200600218A (en) 2005-06-10 2007-03-28 Formulation and direct compression process
DE602006010546D1 (en) 2005-06-16 2009-12-31 Pfizer N- (pyridin-2-yl) sulfonamide derivatives
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
US7605289B2 (en) 2005-06-17 2009-10-20 Amgen, Inc. Benzamide derivatives and uses related thereto
US7585630B2 (en) 2005-06-20 2009-09-08 Decode Genetics Ehf. Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
EP1901741B1 (en) 2005-07-01 2015-09-16 Merck Sharp & Dohme Corp. Process for synthesizing a cetp inhibitor
RU2401832C2 (en) 2005-07-05 2010-10-20 Ф.Хоффманн-Ля Рош Аг Pyridazine derivatives
ES2351057T3 (en) 2005-07-08 2011-01-31 Pfizer Limited MAdCAM antibodies.
ES2382815T3 (en) 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas as glucokinase activators
CA2614518A1 (en) 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
WO2007007688A1 (en) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. 3,5-diamino-1,2,4-triazole derivative
US20080234273A1 (en) 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
EP1910350A1 (en) 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2301929A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
AU2006267387B2 (en) 2005-07-11 2010-11-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
JP5281287B2 (en) 2005-07-13 2013-09-04 Msd株式会社 Heterocyclic-substituted benzimidazole derivatives
RU2443691C2 (en) 2005-07-14 2012-02-27 Транстех Фарма, Инк. Urea glucokinase activators
AU2006272922A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
UY29694A1 (en) 2005-07-28 2007-02-28 Boehringer Ingelheim Int Methods for preventing and treating metabolic disorders and new pyrazole derivatives-o-glucoside
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as medicaments
US20100160286A1 (en) 2005-08-09 2010-06-24 Astrazeneca Uk Limited Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
CN101232873A (en) 2005-08-11 2008-07-30 霍夫曼-拉罗奇有限公司 Pharmaceutical composition comprising a dpp-iv inhibitor
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
DK1931350T3 (en) 2005-09-14 2014-02-10 Takeda Pharmaceutical Administration of inhibitors of dipeptidyl peptidase
ES2376351T5 (en) 2005-09-14 2014-07-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase for treating diabetes
CN101263135A (en) 2005-09-16 2008-09-10 艾尼纳制药公司 Modulators of metabolism and the treatment of disorders related thereto
BRPI0616195A2 (en) 2005-09-20 2011-06-14 Novartis Ag use of an inhibitor of DPP-IV to reduce hypoglycemic events
EP1945190A1 (en) 2005-09-22 2008-07-23 Swissco Devcelopment AG Effervescent metformin composition and tablets and granules made therefrom
JOP20180109A1 (en) 2005-09-29 2019-01-30 Novartis Ag New Formulation
AU2006306420A1 (en) 2005-10-25 2007-05-03 Merck Sharp & Dohme Corp. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
EP1943301A4 (en) 2005-11-04 2010-01-13 Ls Corp Synthesis of mdh-polymer hybrid particles
CA2633167A1 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
JP2009520763A (en) 2005-12-23 2009-05-28 ノバルティス アクチエンゲゼルシャフト Dpp-iv useful fused heterocyclic compounds as inhibitors
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
KR20080086483A (en) 2006-01-06 2008-09-25 노파르티스 아게 Use of organic compounds
AT517099T (en) 2006-02-15 2011-08-15 Boehringer Ingelheim Int Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions comprising such compounds, their use and production method thereof
WO2007099345A1 (en) 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
PE12212007A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 receptor agonists in methods to increase bone mass and to treat osteoporosis and other conditions characterized by low bone mass, or the combined therapy related to these agonists
US8455435B2 (en) 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
PE02352011A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int pharmaceutical combinations comprising metformin and linagliptin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
PT2020996E (en) 2006-05-16 2012-02-20 Gilead Sciences Inc Method and compositions for treating hematological malignancies
KR20070111099A (en) 2006-05-16 2007-11-21 영진약품공업주식회사 Novel crystalline form of sitagliptin hydrochloride
WO2007137107A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
KR100858848B1 (en) 2006-05-23 2008-09-17 한올제약주식회사 Pharmaceutical compositions and formulations of Metformin extended release tablets
WO2007149797A2 (en) 2006-06-19 2007-12-27 Novartis Ag Use of organic compounds
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
AT503443B1 (en) 2006-06-23 2007-10-15 Leopold Franzens Uni Innsbruck A process for producing an ice surface for ice rinks
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
WO2008022267A2 (en) 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
DE102006042586B4 (en) 2006-09-11 2014-01-16 Betanie B.V. International Trading A method for loading of microparticulate high polymeric carbohydrates with hydrophobic liquid active substances
US7956201B2 (en) 2006-11-06 2011-06-07 Hoffman-La Roche Inc. Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
CL2007003187A1 (en) 2006-11-06 2008-03-07 Boehringer Ingelheim Int Compounds derived from benzyl substituted benzonitrile glucopyranosyl and salts thereof; preparation process; intermediate compounds; process for preparing the intermediate compounds; pharmaceutical composition; and use in the treatment of
JP5337040B2 (en) 2006-11-09 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy and their pharmaceutical compositions and SGLT-2 inhibitors
KR20090097184A (en) 2006-12-06 2009-09-15 스미스클라인 비참 코포레이션 Chemical compounds and uses
ES2319596B1 (en) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. New derivatives of amino-nicotinic and isonicotinic amino acids.
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AR064736A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR agonists
CL2008000133A1 (en) 2007-01-19 2008-05-23 Boehringer Ingelheim Int pharmaceutical composition comprising a compound derived pyrazole-o-glucoside combined with at least a second therapeutic agent; and use of the composition for the treatment of diabetes mellitus, cataract, neuropathy, myocardial infarction, and
CL2008000280A1 (en) 2007-02-01 2008-08-18 Takeda Pharmaceutical pharmaceutical composition in tablet form comprising a granule comprising an active substance which induces a problem easily compression and microcrystalline cellulose compression aid and containing magnesium stearate and
RS51592B (en) 2007-02-01 2011-08-31 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and pioglitazone
DE602008006679D1 (en) 2007-02-06 2011-06-16 Chelsea Therapeutics Inc New compounds, methods for their preparation and their use
WO2008113000A1 (en) 2007-03-15 2008-09-18 Nectid, Inc. Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
ES2529149T3 (en) 2007-04-03 2015-02-17 Mitsubishi Tanabe Pharma Corporation A combination of dipeptidyl peptidase IV inhibitor and a sweetener for use in the treatment of obesity
AU2008242981B2 (en) 2007-04-16 2014-06-12 Smith & Nephew, Inc. Powered surgical system
PE06962009A1 (en) 2007-04-20 2009-06-20 Squibb Bristol Myers Co Crystalline forms of saxagliptin and processes for preparing the same
PE02222009A1 (en) 2007-05-04 2009-03-27 Squibb Bristol Myers Co Compounds [6,6] and [6,7] -biciclicos as agonists coupled receptor protein g GPR119
US8440172B2 (en) 2007-07-09 2013-05-14 Symrise Ag Stable soluble salts of phenylbenzimidazole sulfonic acid at PHS at or below 7.0
AU2008276842C9 (en) 2007-07-19 2014-08-21 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
PE06032009A1 (en) 2007-08-16 2009-06-11 Boehringer Ingelheim Int pharmaceutical composition comprising an SGLT2 inhibitor and a DPP IV
UY31291A1 (en) 2007-08-16 2009-03-31 A pharmaceutical composition comprising a pyrazole derivative-0-glucoside
UY31290A1 (en) 2007-08-16 2009-03-31 A pharmaceutical composition comprising a pyrazole derivative-o-glucoside
PE09382009A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int pharmaceutical composition comprising a benzene derivative substituted glucopyranosyl
PE02972011A1 (en) 2008-08-15 2011-05-26 Boehringer Ingelheim Int DPP-4 inhibitors for wound healing
CA2696579C (en) 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
GB2465132B (en) 2007-09-21 2012-06-06 Lupin Ltd Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
DK2215119T3 (en) 2007-11-13 2013-02-04 Evec Inc Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising the same.
ES2612736T3 (en) 2007-11-16 2017-05-18 Novo Nordisk A/S Stable pharmaceutical compositions comprising liraglutide and degludec
CN101234105A (en) 2008-01-09 2008-08-06 北京润德康医药技术有限公司 Pharmaceutical composition containing diabetosan and vildagliptin and preparation thereof
AU2009205060C1 (en) 2008-01-17 2013-12-19 Mitsubishi Tanabe Pharma Corporation Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
US20090186086A1 (en) 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
TW200936136A (en) 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
AU2009210641A1 (en) 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
MX2010009731A (en) 2008-03-04 2010-09-30 Merck Sharp & Dohme Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor.
NZ588011A (en) 2008-03-05 2012-06-29 Takeda Pharmaceutical Heterocyclic compounds having glucagon antagonistic action useful for treating diabetes
US20090270404A1 (en) 2008-03-31 2009-10-29 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int pharmaceutical composition comprising an inhibitor of dipeptidyl peptidase-4 (DPP4) and a companion drug
PE01562010A1 (en) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Treatment of NAFLD
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "Treatment for diabetes in patients unsuitable for therapy with metformin"
JP2010053576A (en) 2008-08-27 2010-03-11 Sumitomo Forestry Co Ltd Mat for paving
RU2011113823A (en) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Combination therapy for the treatment of diabetes and related conditions it
UY32177A (en) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Treatment of diabetes in patients with insufficient glycemic control despite therapy drug, oral or not, antidiabetic
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
WO2010072776A1 (en) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (en) 2009-01-29 2011-03-16 Boehringer Ingelheim Int DPP4 inhibitors and pharmaceutical compositions comprising them, useful for treating metabolic diseases in pediatric patients, particularly type 2 diabetes mellitus
JP2012517977A (en) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Antidiabetic agents including dpp-4 inhibitors (linagliptin) in combination with other antidiabetic agents optionally
NZ594487A (en) 2009-02-13 2013-11-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
UY32427A (en) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh pharmaceutical composition, pharmaceutical form, process for their preparation, methods of treatment and uses thereof
TW201031661A (en) 2009-02-17 2010-09-01 Targacept Inc Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
JP2012520868A (en) 2009-03-20 2012-09-10 ファイザー・インク 3-oxa-7-azabicyclo [3.3.1] nonane
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
WO2010140111A1 (en) 2009-06-02 2010-12-09 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
US20120059011A1 (en) 2009-06-15 2012-03-08 Nicholas Birringer Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
CN109223724A (en) 2009-07-21 2019-01-18 凯克斯生物制药公司 Ferric citrate dosage forms
BR112012007234A2 (en) 2009-10-02 2016-04-05 Boehringer Ingelheim Int A pharmaceutical combination comprising a DPP-4 inhibitor and metformin, as well as its use and its preparation process
US20110236477A1 (en) 2009-10-02 2011-09-29 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
JP5446716B2 (en) 2009-10-21 2014-03-19 大正製薬株式会社 The method of producing arginine and carnitine containing tablets
KR20170136017A (en) 2009-11-27 2017-12-08 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP2010070576A (en) 2009-12-28 2010-04-02 Sato Pharmaceutical Co Ltd Rapidly soluble tablet
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
MX2012012438A (en) 2010-05-05 2012-11-29 Boehringer Ingelheim Int Pharmaceutical formulations comprising pioglitazone and linagliptin.
EA201201508A1 (en) 2010-05-05 2013-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Combined therapy
WO2011154496A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
US8486453B2 (en) 2010-06-22 2013-07-16 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AU2011295837B2 (en) 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012088682A1 (en) 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd. 2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
CA2826391C (en) 2011-02-01 2017-01-24 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int pharmaceutical compositions of metformin, linagliptin and SGLT-2 inhibitor
CN103596954B (en) 2011-05-10 2016-10-26 桑多斯股份公司 Acid polymorph Linagliptin
JP5876150B2 (en) 2011-07-15 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted quinazoline, use of these these preparation and pharmaceutical compositions
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US9139802B2 (en) 2012-01-04 2015-09-22 The Procter & Gamble Company Active containing fibrous structures with multiple regions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6374862B2 (en) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Autoimmune diabetes, in particular, xanthine derivatives as dpp-4 inhibitor for use in the treatment of lada
WO2013174769A1 (en) 2012-05-25 2013-11-28 Boehringer Ingelheim International Gmbh Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
WO2013179307A2 (en) 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
EP2908806A1 (en) 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
US20140100292A1 (en) 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
CN105188706A (en) 2013-03-15 2015-12-23 勃林格殷格翰国际有限公司 Use of linagliptin in cardio- and renoprotective antidiabetic therapy
MX2015014512A (en) 2013-04-18 2016-02-09 Boehringer Ingelheim Int Pharmaceutical composition, methods for treating and uses thereof.
JP2016518438A (en) 2013-05-17 2016-06-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング DPP-4 combination of the inhibitor and α- glucosidase inhibitor
WO2014198906A1 (en) 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for treating diabetes and its complications
EP3110449A1 (en) 2014-02-28 2017-01-04 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2016059219A1 (en) 2014-10-17 2016-04-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof

Also Published As

Publication number Publication date
ECSP088866A (en) 2008-12-30
JP6143809B2 (en) 2017-06-07
TWI500423B (en) 2015-09-21
WO2007128761A2 (en) 2007-11-15
CN107252430A (en) 2017-10-17
JP2013199503A (en) 2013-10-03
CL2012002526A1 (en) 2012-12-21
IL195031D0 (en) 2009-08-03
JP2013199505A (en) 2013-10-03
KR20140048344A (en) 2014-04-23
US20110065731A1 (en) 2011-03-17
ZA200808282B (en) 2009-08-26
EP2351568A3 (en) 2011-11-23
JP2013213064A (en) 2013-10-17
HRP20140645T1 (en) 2014-09-26
CN108635355A (en) 2018-10-12
UY30321A1 (en) 2008-01-02
SI2015754T1 (en) 2014-05-30
KR20190015625A (en) 2019-02-13
JP2018193408A (en) 2018-12-06
CN101460173A (en) 2009-06-17
EP2397142A3 (en) 2012-03-28
PH12013501790A1 (en) 2014-09-22
ES2474866T3 (en) 2014-07-09
JP5813293B2 (en) 2015-11-17
JP2010159305A (en) 2010-07-22
BRPI0711308A2 (en) 2011-12-06
JP2009535381A (en) 2009-10-01
CL2012002528A1 (en) 2012-12-21
EP2351568A2 (en) 2011-08-03
HK1204548A1 (en) 2015-11-27
NZ609765A (en) 2014-12-24
TW201433316A (en) 2014-09-01
US20140135348A1 (en) 2014-05-15
JP2015180686A (en) 2015-10-15
CA2897719A1 (en) 2007-11-15
CN102846619A (en) 2013-01-02
US8673927B2 (en) 2014-03-18
PE02352011A1 (en) 2011-04-14
JP5927146B2 (en) 2016-05-25
AU2007247141A1 (en) 2007-11-15
US9173859B2 (en) 2015-11-03
US20170087160A1 (en) 2017-03-30
AU2007247141B2 (en) 2013-09-12
EA201300213A1 (en) 2013-06-28
US8232281B2 (en) 2012-07-31
CA2897719C (en) 2019-06-18
US10080754B2 (en) 2018-09-25
NZ572863A (en) 2012-01-12
KR101806786B1 (en) 2017-12-08
KR20170136018A (en) 2017-12-08
EP2397142A2 (en) 2011-12-21
DK2015754T3 (en) 2014-06-10
PT2015754E (en) 2014-04-23
MX2008014025A (en) 2008-11-14
CA2833705C (en) 2017-03-07
US20160000798A1 (en) 2016-01-07
TWI524894B (en) 2016-03-11
KR20140048345A (en) 2014-04-23
SG171648A1 (en) 2011-06-29
UA102669C2 (en) 2013-08-12
CA2875706A1 (en) 2007-11-15
KR20150082668A (en) 2015-07-15
KR20090021152A (en) 2009-02-27
CA2875706C (en) 2016-07-26
CL2012002527A1 (en) 2012-12-21
EA200802204A1 (en) 2009-04-28
CN102125560A (en) 2011-07-20
AR060757A1 (en) 2008-07-10
TW200808323A (en) 2008-02-16
CA2651019C (en) 2015-09-22
WO2007128761A3 (en) 2008-03-06
KR101655754B1 (en) 2016-09-08
KR20160107361A (en) 2016-09-13
US20180353513A1 (en) 2018-12-13
MX358618B (en) 2018-08-29
NO20084341L (en) 2008-12-02
JP2013199504A (en) 2013-10-03
RS53272B (en) 2014-08-29
EP2015754B1 (en) 2014-04-09
KR101558938B1 (en) 2015-10-08
PH12013501791A1 (en) 2014-09-22
CN104095854A (en) 2014-10-15
JP2017105849A (en) 2017-06-15
CA2833705A1 (en) 2007-11-15
ME01787B (en) 2014-09-20
EP2407168A1 (en) 2012-01-18
EP2015754A2 (en) 2009-01-21
JP5734564B2 (en) 2015-06-17
CA2651019A1 (en) 2007-11-15
CY1115350T1 (en) 2017-01-04
US20070281940A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
RU2401265C2 (en) Compounds and compositions as protein kinase inhibitors
US4558051A (en) Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
JP4886700B2 (en) The composition of 5ht2c receptor modulators and methods of use thereof
EP2170309B1 (en) 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
US20070281940A1 (en) Uses of dpp-iv inhibitors
ES2420860T3 (en) Heterocyclic amino compounds used as inhibitors PDE9
JP6104989B2 (en) Treatment of diabetic patients genotype was identified by dpp-iv inhibitors such linagliptin
CA2498051C (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
US20170151249A1 (en) Combination therapy
CA2752437C (en) Antidiabetic medications
CA2183562A1 (en) Intracellular signalling mediators
Williams et al. Amlodipine pharmacokinetics in healthy volunteers
US20080070922A1 (en) Combination of Organic Compounds
TWI265163B (en) Novel pyrido[2,1-a]isoquinoline derivatives
CY1108355T1 (en) COMPOSITIONS AND METHOD FOR COMBINED antiviral therapy
JPH09512834A (en) cGMP-PDE inhibitors for the treatment of erectile dysfunction
JP2009504599A (en) The pharmaceutical compositions containing the dpp-iv inhibitors
NO334992B1 (en) Pyrazolo, methods for their preparation, intermediates, pharmaceutical compositions and kits as well as their use in the treatment of disease
EA200201271A1 (en) Inhibitors 11-beta-hydroxysteroid degydrogenase type 1
WO2005011581A3 (en) Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006127530A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
NO333815B1 (en) Beta-amino heterocyclic dipeptidylpeptidaseinhibitorer, use thereof for the preparation of a medicament for the treatment or prevention of diabetes, and pharmaceutical composition comprising the compound.
US20120165251A1 (en) Diabetes therapy
AR035665A1 (en) Imidazoquinolines and 6,7,8,9-tetrahidroimidazoquinolinas, pharmaceutical compositions comprising them, use of these compounds in the preparation of medicines, and intermediates useful in the synthesis of such compounds
AT368647T (en) Pharmaceutical composition and their use as inhibitors of the dipeptidyl peptidase IV (DPP-IV)

Legal Events

Date Code Title Description
FC Refusal